Continuing our ASCO20 coverage with another Preview in the pre-meeting series, we turn our attention to a particular modality of keen interest to many of our readers.
In this latest article, we highlight ten areas within the niche and include an array of companies, both big and small, across Pharma and Biotechs.
Some of them have some nice data to share, others will be footnotes to the meeting, but who fits into what category and what can we learn from the abstracts upfront?
To find out more, we looked very carefully at the hints and nuance which inevitably grace the writer’s pen – it’s time to hone in on where are the flourishes and the crossings out this year?
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Boston: The 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics is underway (#Targets19). It’s long been one of our favorite meetings, particularly when held in Boston, and this year there’s a raft of early ideas on offer as to where the targeted therapy field may be going.
Alison Schram, MD. Credit: MSKCC
The success of Ignyta’s entrectinib (acquired by Roche) and Loxo Oncology’s larotrectinib (acquired by Lilly) in targeting NTRK gene fusions has raised interest in targeting other gene fusions, even if they are rare. A new target in a similar vein that has attracted interest recently are fusions involving the neuregulin 1 gene (NRG1).
At this year’s Molecular Targets meeting, Dr Alison Schram, a medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) presented clinical proof of concept data for MCLA-128 (Merus), a bispecific HER2/3 antibody therapy in NRG1 fusion positive cancers.
What did we learn about MCLA-128 and NRG1 at Targets19?
To learn more from our Triple/Targets meeting oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
While many observers attentions have recently been focused on immuno-oncology of late, particularly with respect to checkpoint blockade and CAR T cell therapies, these are not the only class of drugs that are being investigated in the clinic.
Field of dreams or crowded marketplace?
We saw a lot of early preclinical data and especially got to see quite a few new targets at AACR, while next month ASCO offers a new opportunity to see inital phase 1 data presented in several developmental therapeutic sessions and in the poster halls.
There is no doubt that the oncology R&D niche is becoming increasingly competitive and crowded, which means that companies need to think carefully about how they can clearly differentiate themselves and position their platform much more assertively than before.
For small biotechs, this also means going beyond offering great preclinical packages to demonstrating proof of concept in the clinic, hence phase 1/2 trials are receiving a lot more attention these days, as potential collaborators and acquirers flock to the poster halls.
Today we have a CEO from one of these emerging biotech companies in the BSB hotseat with a candid discussion about their approach, why they are different, and importantly, where they are heading…
To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.